Brand name : Lenalid
Active substance : Lenalidomide
Strength : 25mg
Manufactured by : Natco pharma
Pack : 30 capsules in a container
Category : Anti-neoplastic drug
Lenalid is belongs to anticancer medication which contains Lenalidomide as an active substance which belongs to thalidomide analogue, the main ingredient which is used as lenalidomide . Lenalid(Lenalidomide) 25mg is used to the disease condition by combining with dexamethasone. Lenalid 25mg consist of some other pharmacological activities like immuno modulatory & anti-angiogenesis. Lenalid(Lenalidomide) 25mg is a prescription drug that can only use under the supervision of medical oncologist.
The indications of Lenalid 25mg are; Lenalid(Lenalidomide) combination with dexamethasone is indicated to treat the patients suffered from multiple myeloma Lenalid is indicated for the patients having transfusion-dependent anemia because of intermediate 1 risk myelodysplastic syndrome along with deletion 5q cytogenetic abnormality without or without addition cytogenetic abnormalities Lenalid(Lenalidomide) is used to treat the patients with mantle cell lymphoma in which its used whose the disease was relapsed or progressed after two before treatment, especially the disease not response with the bortezomib therapy.
Lenalid 25mg involves in the prudence of tumor and factor alpha arrangement, that reinforcement the T-cells and leads to lessening plasma levels of cytokines vascular endothelial growth factor and fundamental fibroblast growth factor. Lenalid(Lenalidomide) 25mg is moreover engaged with the stave off angiogenesis. Lenalidomide is furthermore authorize G1 cell cycle capture and apoptosis of ruinous cells.
The adult usual dose of Lenalid 25mg in myelodysplastic syndromes is 10mg and adminisrated once a day.
For renal damaged patients;
CrCl>60ml/min In Patients should not needed dosage adjustment of Lenalid(Lenalidomide)
CrCl 30 to 60ml/min In Patients, 5mg of Lenalid should administre orally as once daily
CrCl<30ml/min In Patient, 2.5mg of Lenalid(Lenalidomide) should be given orally as a once daily.
Drops to <50000/mcL, treatment should be interrupted. Back to > or equal to 50000/mcL, follow the Lenalid(Lenalidomide) of 5mg per day.
Drops to <500/mcL, treatment should be delayed. Back to > or equal to 500/mcL, treatment should be follow to 5mg per day.
In this disease, concomitant use of dexamethasone with Lenalid. The regular dose of Lenalid(Lenalidomide) is 25mg should be given as once in a day on day 1 to 21. The dose of dexamethasone; Dexamethasone 40mg should be continued on day 1 to 4, 9 to 12 & 17 to 20 of each period of 28-day cycles. Patient with greater than 75 years, dexamethasone 20mg should be prescribed on day 1, 8, 15, & 22.
Mantle cell lymphoma;
absorbed rapidly withpeak plasma concentration is between 0.625 and 1.5 hrs. combining with food will not change the prolong of absorption but dose decrease in Cmax.
bounding of plasma protein is 30%
mainly metabolized in two metabolites is hydroxy-lenalidomide and N-acetyl-lenalidomide.
primarily eliminated in renal route and the dose excreted via urine 90% and feces 4% and half-life is 3hrs
MANTLE CELL LYMPHOMA
The usual dose of Lenalid(Lenalidomide) for this disease is 25mg should be given orally as once daily. For renal damaged patients; CrCl 30 to 60ml/min in patient, Lenalid 10mg should be given as once daily. CrCl<30ml/min in patients, Lenalid(Lenalidomide) 15mg should be used for q48hr. Pediatrics; The safety & efficiency of Lenalidomide has not been decribed in pediatric patients with age of <18 years.
Interaction of Lenalid(Lenalidomide) 25mg with digoxin leads to increased concentration of digoxin causes increased risk of adverse effects related to digoxin. Interaction of Lenalid 25mg with Erythropoietic agents, cause to produced rises in risk of thrombosis. Discuss with the patients prior to starting this combination treatment. Interaction of Lenalid(Lenalidomide) 25mg with warfarin, will produce increased exposure of hemorrhage disorders. check the INR value & prothrombin time.
When pregnancy period the drug is contraindicated The patients are contraindicated to hypersensitivity reaction and the Lenalid(Lenalidomide) 25mg component.
The missed dose of Lenalid(Lenalidomide) 25mg should be avoided. If missed dose founded, then patients should be consulting with doctor specialized in oncologist Regulate the usual dosing schedule.
Over dosage of Lenalid(Lenalidomide) 25mg will cause neutropenia & thrombocytopenia as mainly common side effects. Give the patient general supportive treatment. check the blood cells counts regularily during the treatment.
Second primary malignancies :
Hepatotoxicity , Hypersensitivity reactions, Thyroid dysfunction, Fetal toxicity, Hematological toxicity, Tumor lysis syndrome, Tumor flare reactions, Increase of mortality rate.
Common side effects;
Diabetes mellitus, Rash, Insomnia, Depression, Deep vein thrombosis, Myocardial infraction, Renal failure, Squamous cell carcinoma, Basal cell carcinoma, Fatigue, Asthenia, Pyrexia, Pain, Diarrhea, Dyspepsia, Bone pain, Neck pain, Respiratory infections, UTI, Influenza, Sepsis, Headache, Anemia, Loss of appetite, Hypokalemia, Hyperglycemia, Hypocalcaemia, Dehydration, Gout.
The some of the common life-threatening condition like :
Venous & arterial thromboembolism
Blood clotting effects
Embryo fetal damage
For all these conditions, some supportive measures should be used and provide safety measures.